borderline significantP =0.07
A borderline significant association ( P =0.07) between ER- β serum bioactivity and ER-negative breast cancer emerged after adjustment for ER- α serum bioactivity ( Table 4 ).
A borderline significant association ( P =0.07) between ER- β serum bioactivity and ER-negative breast cancer emerged after adjustment for ER- α serum bioactivity ( Table 4 ).
In addition, there was also a clear trend, although not significant, towards higher serum ER- β bioactivity in ER-negative breast cancer cases compared with controls ( Table 1 ).